Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Eshghi, P
116  Ergebnisse:
Personensuche X
?
1

PB0281 Establishment of a National Patient-Based Pediatric ..:

Eshghi, P. ; Kamfar, S. ; Alavi, S..
Research and Practice in Thrombosis and Haemostasis.  7 (2023)  - p. 101427 , 2023
Link: https://doi.org/10.1016/..
 
?
2

PB1534 A Detailed Phenomenological Study on General Health ..:

Feizi, F. ; Eshghi, A. ; Shormeij, Z....
Research and Practice in Thrombosis and Haemostasis.  7 (2023)  - p. 101936 , 2023
Link: https://doi.org/10.1016/..
 
?
3

PB1387 Frequency of Inherited Platelet Secretion Disorders ..:

Shahbazi, M. ; Ahmadinejad, M. ; Eshghi, P.
Research and Practice in Thrombosis and Haemostasis.  7 (2023)  - p. 101521 , 2023
Link: https://doi.org/10.1016/..
 
?
4

OC 50.3 Inhibitor Development Upon Switch After 50 EDs from..:

Miri, S. ; Rosendaal, F. ; Kavakli, K....
Research and Practice in Thrombosis and Haemostasis.  7 (2023)  - p. 100426 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Hemolytic disease of the fetus and newborn caused by anti-H..:

Sarihi, R. ; Ahmadnejad, M. ; Mohammadi, S....
Transfusion and Apheresis Science.  60 (2021)  1 - p. 102913 , 2021
Link: https://doi.org/10.1016/..
 
?
6

PSY57 - A COMPARISON BETWEEN ON DEMAND USAGE OF RFVIIA VS P..:

Seyedifar, M. ; Khedmati, J. ; Eshghi, P.
Value in Health.  21 (2018)  - p. S445 , 2018
Link: https://doi.org/10.1016/..
 
?
7

Prediction of factorVIIIinhibitor development in theSIPPETc..:

Spena, S. ; Garagiola, I. ; Cannavò, A....
Journal of Thrombosis and Haemostasis.  16 (2018)  4 - p. 778-790 , 2018
Link: https://doi.org/10.1111/..
 
?
8

PSY66 - AN EFFICIENT AMBULATORY SERVICE MODEL FOR HEMOPHILI..:

Davari, M. ; Sadeghi, A. ; Zargaran, M...
Value in Health.  21 (2018)  - p. S447 , 2018
Link: https://doi.org/10.1016/..
 
?
9

Safety and effectiveness of room temperature stable recombi..:

Kavakli, K. ; Demartis, F. ; Karimi, M....
Haemophilia.  23 (2017)  4 - p. 575-582 , 2017
Link: https://doi.org/10.1111/..
 
?
10

A Patient Level Simulation Model:

Gharibnaseri, Z ; Davari, M ; Cheraghali, A...
Value in Health.  19 (2016)  7 - p. A398 , 2016
Link: https://doi.org/10.1016/..
 
?
11

Cost-Utility of Prophylaxis VS. On-Demand Treatment In Seve..:

Gharibnaseri, Z ; Davari, M ; Cheraghali, A...
Value in Health.  19 (2016)  7 - p. A591 , 2016
Link: https://doi.org/10.1016/..
 
?
12

A Comparison Between Recombinant Activated Factor VII (Aryo..:

Faranoush, M. ; Abolghasemi, Hassan ; Toogeh, Gh....
Clinical and Applied Thrombosis/Hemostasis.  21 (2014)  8 - p. 724-728 , 2014
Link: https://doi.org/10.1177/..
 
?
13

A Comparison of Efficacy Between Recombinant Activated Fact..:

Faranoush, M. ; Abolghasemi, H. ; Mahboudi, F....
Clinical and Applied Thrombosis/Hemostasis.  22 (2014)  2 - p. 184-190 , 2014
Link: https://doi.org/10.1177/..
 
?
14

Establishing a harmonized haemophilia registry for countrie..:

Alzoebie, A. ; Belhani, M. ; Eshghi, P....
Haemophilia.  19 (2013)  5 - p. 668-673 , 2013
Link: https://doi.org/10.1111/..
 
?
15

Evaluation of the FXIII deficiency prophylaxis intervals in..:

Naderi, M. ; Eshghi, P. ; Cohan, N...
Haemophilia.  19 (2013)  3 - p. , 2013
Link: https://doi.org/10.1111/..
 
1-15